Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM. In the present study, we investigated the preclinical ac...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Santo, Loredana, Hideshima, Teru, Kung, Andrew L., Tseng, Jen-Chieh, Tamang, David, Yang, Min, Jarpe, Matthew, van Duzer, John H., Mazitschek, Ralph, Ogier, Walter C., Cirstea, Diana, Rodig, Scott, Eda, Homare, Scullen, Tyler, Canavese, Miriam, Bradner, James, Anderson, Kenneth C., Jones, Simon S., Raje, Noopur
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Lymphoid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337713/
https://ncbi.nlm.nih.gov/pubmed/22262760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-387365
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items